Biogen
Litifilimab
Subacute Cutaneous Lupus Erythematosus
Countdown
106days
Phase 3 readout · Oct 20, 2026
What's at stake
Phase 3 trial results for Litifilimab in Subacute Cutaneous Lupus Erythematosus are due Oct 20, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“both litifilimab Phase 3 systemic lupus (SLE) studies expected to read out in Q4 2026”